Human medicines European public assessment report (EPAR): Adzynma, rADAMTS13, Date of authorisation: 01/08/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Enrylaze, crisantaspase, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Data access to medicinal products for human use - Chapter 5 Annex A: Product data elements accessible by stakeholder group

Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2026

Human medicines European public assessment report (EPAR): Soliris, eculizumab, Date of authorisation: 20/06/2007, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR): Fulphila, pegfilgrastim, Date of authorisation: 20/11/2018, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Sibnayal, potassium citrate,potassium hydrogen carbonate, Date of authorisation: 30/04/2021, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Hulio, adalimumab, Date of authorisation: 17/09/2018, Revision: 19, Status: Authorised

Agenda of the CAT meeting 18-20 February 2026